This study tests new treatments for a type of skin cancer called melanoma. The treatments are experimental drugs called fianlimab (REGN3767) and cemiplimab (REGN2810). These drugs are combined to see if they work better than existing drugs, relatlimab and nivolumab, which are already used to treat melanoma under the brand name Opdualag™. Researchers want to find out how safe these new drugs are and how well they work. They will also study any possible side effects and how the drugs act in the body over time.

The study includes adults with advanced melanoma, either stage III or IV. Participants cannot have received previous treatments for their advanced cancer, and they need to be healthy enough to join, with good bone marrow, liver, and kidney function. Some people cannot join, like those with certain other kinds of melanoma or ongoing autoimmune diseases.

• The study will compare the new drugs with existing treatments.
• Participants will be monitored for side effects and drug effectiveness.
• Eligibility depends on cancer stage and overall health.